FDA approves new drug for mantle cell lymphoma

The US Food and Drug Administration has granted an accelerated approval to Calquence (acalabrutinib), a new kinase inhibitor for the treatment of adults with mantle cell lymphoma, a rare and fast-growing type of non-Hodgkin lymphoma.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States